Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives itch and is involved in inflammation and skin barrier ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

The following is a summary of “Validity of diagnosis codes to identify a dermatomyositis cohort from electronic health records,” published in the January 2025 issue of Dermatology by Silberzweig et al ...

Some simple surgeries may now require two separate procedures, as the shortage of funding in healthcare has prompted the ...

Detailed price information for Theralase Technologies Inc (TLTFF) from The Globe and Mail including charting and trades.

Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the ...

Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCES ...

This Press Release updates numerical list in reference sectionTheralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of th ...

The absence of proper education about syphilis could see cases rise even further, warns Dr Donald Grant of The Independent ...

Rocket Pharmaceuticals, Inc.'s innovative therapies show promise after FDA setbacks. With potential $1B+ markets, RCKT offers ...

T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.